The Pacific Cancer Research Consortium (PCRC) brings together community cancer treatment centers in the Western United States to form an NCI Community Oncology Research Program (NCORP) Community Site. The PCRC includes Swedish Cancer Institute in Seattle and its former U10 affiliates (the Puget Sound Oncology Consortium), Providence Portland Medical Center in Portland and its former Community Clinical Oncology Program affiliates (the Western Oncology Research Consortium), and Mountain States Tumor Institute in Boise. Under a multiple PI/PD structure, the 3 primary components of the PCRC will define and facilitate the clinical trial and cancer care delivery research agenda across 24 participating components and 14 sub-components in Washington, Oregon, Idaho, Alaska, and California. Each of our primary component sites has decades of experience conducting clinical trials in cancer and plan to participate in all aspect of study design and conduct NCI-approved clinical studies and cancer care delivery research, with particular focus on facilitating the participation of minorities and underserved populations across all study types and settings within our catchment areas, providing bio specimen banking and sharing practices within the participating institutions and with our research bases, and incorporating genomic medicine and targeted therapies into our portfolio of research capabilities. We also plan to build a multicenter infrastructure and research agenda for cancer care delivery research to support the trials proposed by the NCTN, allowing us to participate in the development of novel approaches to CC DR studies.

Public Health Relevance

This joint application and the proposed structure com e from our desire to create the strongest NCORP application from our region that will excel in patient accrual, and foster new and close collaboration between investigators. We believe that our structure will accelerate the translation of knowledge gained from cancer clinical trials into clinical practice and enhance the science, the treatments, and the delivery of care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
1UG1CA189953-01
Application #
8790837
Study Section
Special Emphasis Panel (ZCA1-RTRB-E (M1))
Program Officer
Pearson, Deborah
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$1,338,135
Indirect Cost
$81,016
Name
Swedish Medical Center, First Hill
Department
Type
DUNS #
079264420
City
Seattle
State
WA
Country
United States
Zip Code
98122
Puvvada, Soham D; Stiff, Patrick J; Leblanc, Michael et al. (2016) Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. Br J Haematol 174:686-91
Goss, Paul E; Ingle, James N; Pritchard, Kathleen I et al. (2016) Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med 375:209-19
Unger, Joseph M; Hershman, Dawn L; Arnold, Kathryn B et al. (2016) Stepwise development of a cancer care delivery research study to evaluate the prevalence of virus infections in cancer patients. Future Oncol 12:1219-31
Lara Jr, Primo N; Moon, James; Hesketh, Paul J et al. (2016) SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay. J Thorac Oncol 11:420-5
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95
Stephens, Deborah M; Li, Hongli; LeBlanc, Michael L et al. (2016) Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. J Clin Oncol 34:2997-3004
Puvvada, Soham D; Li, Hongli; Rimsza, Lisa M et al. (2016) A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. Leuk Lymphoma 57:2359-69
Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16
Till, Brian G; Li, Hongli; Bernstein, Steven H et al. (2016) Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601. Br J Haematol 172:208-18
Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12

Showing the most recent 10 out of 13 publications